Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Nichols

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Science (New York, N.Y.)|June 21, 1991
Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxinR W Finberg, S M Wahl, J B Allen, et al.
Annals of the New York Academy of Sciences|December 30, 1991
Protein engineering of DAB-IL-2 fusion toxins to increase biologic potencyT Kiyokawa, D P Williams, C E Snider, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1992
Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443D A Hullett, A S Landry, D E Eckoff, et al.
Cancer Research|July 15, 1989
Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemiaT Kiyokawa, K Shirono, T Hattori, et al.
Transplantation Proceedings|February 1, 1993
DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survivalD A Hullett, A S Landry, D E Eckhoff, et al.
European Journal of Immunology|April 1, 1990
Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cellsC A Waters, P A Schimke, C E Snider, et al.
The Journal of Biological Chemistry|November 5, 1991
Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxinsJ P Shaw, D E Akiyoshi, D A Arrigo, et al.
Atherosclerosis|September 27, 1996
Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosisD D Miller, R G Bach, F O Tio, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Science (New York, N.Y.)|June 21, 1991
Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxinR W Finberg, S M Wahl, J B Allen, et al.
Annals of the New York Academy of Sciences|December 30, 1991
Protein engineering of DAB-IL-2 fusion toxins to increase biologic potencyT Kiyokawa, D P Williams, C E Snider, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1992
Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443D A Hullett, A S Landry, D E Eckoff, et al.
Cancer Research|July 15, 1989
Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemiaT Kiyokawa, K Shirono, T Hattori, et al.
Transplantation Proceedings|February 1, 1993
DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survivalD A Hullett, A S Landry, D E Eckhoff, et al.
European Journal of Immunology|April 1, 1990
Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cellsC A Waters, P A Schimke, C E Snider, et al.
The Journal of Biological Chemistry|November 5, 1991
Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxinsJ P Shaw, D E Akiyoshi, D A Arrigo, et al.
Atherosclerosis|September 27, 1996
Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosisD D Miller, R G Bach, F O Tio, et al.
Blood|January 15, 1998
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2C F LeMaistre, M N Saleh, T M Kuzel, et al.
Journal of the American Academy of Dermatology|July 23, 1998
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesM N Saleh, C F LeMaistre, T M Kuzel, et al.
Pageof 4